Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 14, 2025

National Trends and In-Hospital Outcomes of Hematopoietic Stem Cell Transplant in Myelodysplastic Syndromes, 2016–2020

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAniket Vijay RaoASAditya SanjeeviDIDaniel Jose Idoate-Domench

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals increased HSCT usage in MDS patients, highlighting age and insurance disparities.

Key Points

  • Among 30,460 patients, 4,980 (16.16%) had myelodysplastic syndromes and underwent HSCT.
  • MDS patients were older (median age 62) and had more comorbidities compared to non-MDS patients, indicating higher health risks.
  • From 2016 to 2020, the percentage of MDS patients receiving HSCT increased from 13.20% to 17.32% before a slight decline in 2020.
  • MDS patients faced higher in-hospital mortality (aOR 1.33) and worse outcomes, emphasizing disparities in care.

Cite This Study

Rao et al. (2025) studied this question.

synapsesocial.com/papers/689a02afe6551bb0af8cc120https://doi.org/10.21203/rs.3.rs-7023668/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1In-hospital mortality and complications are increased in hematopoietic stem cell transplant recipients with myelodysplastic syndromes2026
  2. 2Trends in transplantation for patients with myelodysplastic syndrome across recent decades: A registry-based study on behalf of the chronic malignancies working of the EBMT2025
  3. 3Differential trends in survival after allogeneic transplantation for MDS and MDS/MPN in a real-world experience2025
  4. 4Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes2025
  5. 5Impact of allogeneic transplant vs hypomethylating agents in high-risk myelodysplastic syndromes: A prisma-guided systematic review2025